Trends in snakebite envenomation therapy: Scientific, technological and public health considerations

Current Pharmaceutical Design

Volumn 13, Issue 28, 2007, Pages 2935-2950

  Gutiérrez, José María ^a   Lomonte, Bruno ^a   León, Guillermo ^a   Rucavado, Alexandra ^a   Chaves, Fermando ^a   Angulo, Yamileth ^a  

^a UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

Antivenom; Hemorrhage; Inflammation; Metalloproteinase inhibitors; Necrosis; Phospholipase A2 inhibitors; Snake venom

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; ARISTOLOCHIC ACID; AUROTHIOMALATE; BATIMASTAT; COMPLEMENTARY DNA; CROMOGLYCATE DISODIUM; CROTOXIN; ENZYME INHIBITOR; HYALURONIDASE ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; MARIMASTAT; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; MYOTOXIN INHIBITOR; NEUROTOXIN; NEUTRALIZING ANTIBODY; PHOSPHOLIPASE A2 INHIBITOR; PLASMID DNA; RECOMBINANT DNA; SNAKE VENOM; STEROID; SURAMIN; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENOM ANTISERUM; VIPERID;

ANAPHYLACTIC SHOCK; ANGIONEUROTIC EDEMA; BINDING AFFINITY; BLEEDING; BLISTER; BRONCHOSPASM; CELL REGENERATION; CHILL; CLINICAL PROTOCOL; CLINICAL TRIAL; COLIC; COMPLEMENT SYSTEM; COMPUTER AIDED DESIGN; COST EFFECTIVENESS ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MANUFACTURE; DRUG PROTEIN BINDING; DRUG PURIFICATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG STABILITY; DRUG STORAGE; DRUG TREATMENT FAILURE; EDEMA; ENVENOMATION; EXTRACELLULAR MATRIX; HEALTH CARE ACCESS; HUMAN; HYPOTENSION; IMMUNOTHERAPY; INFLAMMATION; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; MOLECULAR DOCKING; MUSCLE NECROSIS; MUSCULOSKELETAL PAIN; NAUSEA; NONHUMAN; PATHOGENESIS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN STRUCTURE; PUBLIC HEALTH; REPEATED DRUG DOSE; REVIEW; SHELF LIFE; SKIN NECROSIS; SNAKE; SNAKEBITE; TISSUE INJURY; TISSUE REPAIR; TREND STUDY; UNSPECIFIED SIDE EFFECT; VOMITING; ANIMAL; CHEMISTRY; METABOLISM;

ANIMALS; ANTIVENINS; HUMANS; PUBLIC HEALTH; SNAKE BITES; SNAKE VENOMS;

EID: 38449100299     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207782023784     Document Type: Review

References (230)

1. Swaroop S, Grab B. Snakebite mortality in the world. Bull WHO 1954; 10: 35-76.
2. Chippaux JP. Snake-bites: appraisal of the global situation. Bull WHO 1998; 76: 515-24.
3. Warrell DA, Arnett C. The importance of bites by the saw-scaled or carpet viper (Echis carinatus). Epidemiological studies in Nigeria and a review of the world literature. Acta Trop 1976; 33: 307-41.
4. Sharma SK, Chappuis F, Jha N, Bovier PA, Loutan L, Koirala S. Impact of snake bites and determinants of fatal outcomes in southeastern Nepal. Am J Trop Med Hyg 2004; 71: 234-8.
5. Warrell DA. In: Gopalakrishnakone P, Tan CK Eds. Recent Advances in Toxinology Research. Singapore, National University of Singapore 1992; 121-53.
6. Warrell DA. In: Meier J, White J Eds. Handbook of Clinical Toxicology of Animal Venoms and Poisons. Florida, CRC Press 1995; 493-594.
7. Warrell DA. In: Meier J, White J Eds. Handbook of Clinical Toxicology of Animal Venoms and Poisons. Florida, CRC Press 1995; 433-92.
8. Fan HW, Cardoso JL. Clinical toxicology of snake bites in South America. In: Meier J, White J Eds. Handbook of Clinical Toxicology of Animal Venoms and Poisons. Florida, CRC Press 1995; 667-88.
9. Gutiérrez JM. In: Meier J, White J Eds. Handbook of Clinical Toxicology of Animal Venoms and Poisons. Florida, CRC Press 1995; 645-65.
10. Warrell DA. In: Bon C, Goyffon M Eds. Envenomings and Their Treatments. Lyon, Fondation Marcel Mérieux 1996; 63-76.
11. Azevedo-Marques MM, Cupo P, Coimbra TM, Hering SE, Rossi MA, Laure CJ. Myonecrosis, myoglobinuria and acute renal failure induced by South American rattlesnake (Crotalus durissus terrificus) envenomation in Brazil. Toxicon 1985; 23: 631-6.
12. White J. In: Meier J, White J Eds. Handbook of Clinical Toxicology of Animal Venoms and Poisons. Florida, CRC Press 1995; 595-617.
13. Bon C. In: Bon C, Goyffon M Eds. Envenomings and Their Treatments. Lyon, Fondation Marcel Mérieux 1996; 3-9.
14. Vital Brazil O. History of the primordia of snake-bite accident serotherapy. Mem Inst Butantan 1987; 49: 7-20.
15. Meier J. In: Meier J, White J Eds. Handbook of Clinical Toxicology of Animal Venoms and Poisons. Florida, CRC Press 1995; 689-721.
16. Lalloo D, Theakston RDG. Snake antivenoms. J Toxicol Clin Toxicol 2003; 41: 277-90.
17. Raw I, Guidolin R, Higashi HG, Kelen EMA. In: Tu AT Ed. Handbook of Natural Toxins, Vol 5, Reptile Venoms and Toxins. New York, Marcel Dekker, Inc 1991; 557-81.
18. Pope CG. The action of proteolytic enzymes on the antitoxins and proteins in immune sera. II. Heat denaturation after partial enzyme action. Br J Exp Pathol 1939; 20: 201-12.
19. Grandgeorge M, Véron JL, Lutsch C, Makula MF, Riffard P, Pépin S, et al. In: Bon C, Goyffon M Eds. Envenomings and Their Treatments. Lyon, Fondation Marcel Mérieux 1996; 161-72.
20. Jones RG, Landon J. A protocol for 'enhanced pepsin digestion': a step by step method for obtaining pure antibody fragments in high yield from serum. J Immunol Methods 2003; 275: 239-50.
21. Smith DC, Reddi KR, Laing G, Theakston RG, Landon J. An affinity purified ovine antivenom for he treatment of Vipera berus envenoming. Toxicon 1992; 30: 865-71.
22. 2 antisnake venom by caprylic acid: a fast method for obtaining IgG fragments with large neutralization activity, purity and yield. Toxicon 1989; 27: 297-303.
23. Rojas G, Jiménez JM, Gutiérrez JM. Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production. Toxicon 1994; 32: 351-63.
24. Cardoso JLC, Fan HW, Franca FOS, Jorge MT, Leite RP, Nishioka SA, et al. Randomized comparative trial of three antivenoms in the treatment of envenoming by lance-headed vipers (Bothrops jararaca) in Sao Paulo, Brazil. Q J Med 1993; 86: 315-25.
25. Otero R, Gutiérrez JM, Rojas G, Núñez V, Díaz A, Miranda E, et al. A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia. Correlation between safety and biochemical characteristics of antivenoms. Toxicon 1999; 37: 895-908.
26. Smalligan R, Cole J, Brito N, Laing GD, Mertz BL, Manock S, et al. Crotaline snake bite in the Ecuadorian Amazon: randomised double blind comparative trial of three South American poly-specific antivenoms. BMJ 2004; 329: 1129-35.
27. Ménez A. In: Harvey AL Ed. Snake Toxins. New York, Pergamon Press 1991; 35-90.
28. Gutiérrez JM, Leén G, Lomonte B. Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation. Clin Pharmacokinet 2003; 42: 721-41.
29. Gutiérrez JM, León G, Rojas G, Lomonte B, Rucavado A, Chaves F. Neutralization of local tissue damage induced by Bothrops asper (terciopelo) snake venom. Toxicon 1998; 36: 1529-39.
30. Gutiérrez JM, Ownby CL, Odell GV. Pathogenesis of myonecrosis induced by crude venom and a myotoxin of Bothrops asper. Exp Mol Pathol 1984; 40: 367-79.
31. Moreira L, Gutiérrez JM, Borkow G, Ovadia M. Ultrastructural alterations in mouse capillary blood vessels after experimental injection of venom from the snake Bothrops asper (terciopelo). Exp Mol Pathol 1992; 57: 124-33.
32. Lomonte B, Lundgren J, Johansson B, Bagge U. The dynamics of local tissue damage induced by Bothrops asper snake venom and myotoxin II on the mouse cremaster muscle: an intravital and electron microscopic study. Toxicon 1994; 32: 41-55.
33. Battellino C, Piazza R, da Silva AMM, Cury Y, Farsky SHP. Assessment of efficacy on bothropic antivenom therapy on microcirculatory effects induced by Bothrops jararaca snake venom. Toxicon 2003; 41: 583-93.
34. Otero R, Gutiérrez JM, Núñez V, Robles A, Estrada R, Segura E, et al. Moreno ME & the regional group on antivenom therapy research. A randomized double-blind clinical trial of two antivenoms in patients bitten by Bothrops atrox in Colombia. Trans Royal Soc Trop Med Hyg 1996; 90: 696-700.
35. Trebien HA, Calixto JB. Pharmacological evaluation of rat paw oedema induced by Bothrops jararaca venom. Agents Actions 1989; 26: 292-300.
36. Chaves F, Barboza M, Gutiérrez JM. Pharmacological study of edema induced by venom of the snake Bothrops asper (terciopelo). Toxicon 1995; 33: 31-9.
37. Prasampun S, Walsh J, Awad SS, Harris JB. Envenoming bites by kraits: the biological basis of treatment-resistant neuromuscular paralysis. Brain 2005; 128: 2987-2996.
38. 2 and Fab of the antivenin. Toxicon 1998; 36: 93-114.
39. Scherrmann JM. Antibody treatment of toxin poisoning-Recent advances. Clin Toxicol 1994; 32: 363-75.
40. Riviere G, Choumet V, Audebert F, Sabouraud A, Debray M, Scherrmann JM, et al. Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: toward an optimization of antivenom therapy. J Pharmacol Exp Ther 1997; 281: 1-8.
41. Bon C. Pharmacokinetics of venom toxins and their modification by antivenom therapy. J Toxicol Toxin Rev 2003; 22: 129-38.
42. Chippaux JP, Williams V, White J. Snake venom variability: methods of study, results and interpretation. Toxicon 1991; 29: 1279-303.
43. Gutiérrez JM, Rojas G, Bogarín G, Lomonte B. In: Bon C, Goyffon M Eds. Envenomings and Their Treatments. Lyon, Fondation Marcel Mérieux 1996; 223-31.
44. Otero R, Núñez V, Osorio RG, Gutiérrez JM, Giraldo CA, Posada LE. Ability of six Latin American antivenoms to neutralize the venom of mapaná equis (Bothrops atrox) from Antioquia and Chocó (Colombia). Toxicon 1995; 33: 809-15.
45. Bogarín G, Morais JF, Yamaguchi IK, Stephano MA, Marcelino JR, Nishikawa AK, et al. Neutralization of crotaline snake venoms from Central and South America by antivenoms produced in Brazil and Costa Rica. Toxicon 2000; 38: 1429-41.
46. Theakston RDG, Laing GD, Fielding CM, Freire Lascano A, Touzet JM, Vallejo F, et al. Treatment of snake bites by Bothrops species and Lachesis muta in Ecuador: laboratory screening of candidate antivenoms. Trans R Soc Trop Med Hyg 1995; 89: 550-4.
47. Saravia P, Rojas E, Arce V, Guevara C, López JC, Chaves E, et al. Geographic and ontogenic variability in the venom of the neotropical rattlesnake Crotalus durissus: Pathophysiological and therapeutic implications. Rev Biol Trop 2002; 50: 337-46.
48. Theakston RDG. In: Bon C, Goyffon M Eds. Envenomings and Their Treatments. Lyon, Fondation Marcel Mérieux 1996; 117-26.
49. Fan HW. In: Cardoso JLC, Franca FOS, Fan HW, Málaque CMS, Haddad V. Animais Peconhentos no Brasil. Biologia, Clinica e Terapeutica. Sao Paulo, Sarvier 2003; 380-93.
50. 2: Results of a clinical trial in northern Cameroon. Am J Trop Med Hyg 1999; 61: 1017-18.
51. Moran NF, Newman WJ, Theakston RDG, Warrell DA, Wilkinson D. High incidence of early anaphylactoid reactions to SAIMR polyvalent snake antivenom. Trans R Soc Trop Med Hyg 1999; 92: 69-70.
52. Gawarammana IB, Kularatne SA, Dissanayabe WP, Kumarasiri RP, Senanayake N, Ariyasena H. Parallel infusion of hydrocortisone +/- chlorpheniramine bolus injection to prevent acute adverse reactions to antivenom for snakebites. Med J Aust 2004; 180: 20-3.
53. Jurkovich GJ, Luterman A, McCullar K, Ramenofsky ML, Curreri PW. Complications of Crotalidae antivenin therapy. J Trauma 1988; 28: 1032-7.
54. Fan HW, Marcopito LF, Cardoso JL, Franca FO, Malaque CM, Ferrari RA, et al. Sequential randomised and double blind trial of promethazine prophylaxis against early anaphylactic reactions to antivenom for Rothrops snakebites. BMJ 1999; 318: 1451-2.
55. Premawardhena AP, de Silva CE, Fonseka MMD, Gunatilake SB, de Silva HJ. Low dose subcutaneous adrenaline to prevent acute adverse reactions to antivenom serum in people bitten by snakes: randomized, placebo controlled trial. BMJ 1999; 318: 1041-3.
56. Sutherland SK. Serum reactions. An analysis of commercial antivenoms and the possible role of anticomplementary. Med J Aust 1977; 1: 613-15.
57. Malasit P, Warrell DA, Chantavanich P, Viravan C, Mongkilsapaya J, Singhthong B, et al. Prediction, prevention and mechanism of early (anahylactic) antivenom ractions in victim of snake bites. BMJ 1986; 292:17-20.
58. Montero J, Trejos M, Lomonte B. Efecto del suero antiofidico sobre la actividad hemolitica del complemento humano (in vitro) y de conejo (in vitro e in vivo). Rev Costarric Cienc Méd 1989; 10: 1-10.
59. 2 fragments. Toxicon 1994; 32: 725-34.
60. 2 polyvalent antivenoms: neutralization of systemic effects induced by Bothrops asper venom in mice, extravasation to muscle tissue, and potential of adverse reactions. Toxicon 2001; 39: 793-801.
61. León G, Lomonte B, Gutiérrez JM. Anticomplementary activity of equine whole IgG antivenoms: comparison of three fractionation protocols. Toxicon 2005; 45: 123-8.
62. Otero R, León G, Gutiérrez JM, Rojas G, Toro MF, Barona J, et al. Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without β-propiolactone, in the treatment of Bothrops asper bites in Colombia. Trans R Soc Trop Med Hyg 2006; 100: 1173-82.
63. Chippaux JP. The development and use of immunotherapy in Africa. Toxicon 1998; 36: 1503-6.
64. Otero-Patiño R, Cardoso JLC, Higashi HG, Núñez V, Diaz A, Toro MF, et al. A randomized, blinded, comparative trial of one pepsindigested and two whole IgG antivenoms for Bothrops snake bites in Urabá, Colombia. Am J Trop Med Hyg 1998; 59: 183-9.
65. Wilde H, Thipkong P, Sitprija V, Chaiyabutr N. Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis. Ann Intern Med 1996; 125: 233-6.
66. Theakston RDG, Warrell DA. Crisis in snake antivenom supply for Africa. Lancet 2000; 356: 2104.
67. Theakston RDG, Warrell DA, Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 2003; 41: 541-57.
68. Laing GD, Harrison RA, Theakston RDG, Renjifo JM, Nasidi A, Gutiérrez JM, et al. Polyspecific snake antivenom may help in antivenom-crisis. BMJ 2003; 326: 447-8.
69. Chippaux JP. In: Mńez A Ed, Perspectives in Molecular Toxinology. New York, John Wiley & Sons Co. 2002; 457-72.
70. Looarcesuwan S, Vimvan C, Warrell DA. Factors contributing to fatal snake bite in the rural tropics: analysis of 46 cases in Thailand. Trans R Soc Trop Med Hyg 1988; 82: 930-4.
71. Gutiérrez; JM, Theakston RDG, Warrell DA. Confronting the neglected problem of snake bite envenoming: the need for a global partnership. PLoS Med 2006; 3: 727-31.
72. Serrano SMT, Shannon JD, Wand D, Camargo ACM, Fox JW. A multifaceted analysis of viperid snake venoms by two-dimensional gel electrophoresis: an approach to understanding venom proteomics. Proteomics 2005; 5: 501-10.
73. Harrison RA. Development of venom toxin-specific antibodies by DNA immunization: rationale and strategies to improve therapy of viper envenoming. Vaccine 2004; 22: 1648-55.
74. Harrison RA, Moura-da-Silva AM, Laing GD, Wu Y, Richards, A, Broadhead A, et al. Antibody from mice immunized with DNA encoding the carboxyl-disintegrin and cysteine-rich domain (JD9) of the hemorrhagic metalloproteinase, jararhagin, inhibits the main lethal component of viper venom. Clin Exp Immunol 2000; 121: 358-63.
75. Raweerith R, Ratanabanangkoon K. Fractionation of equine antivenom using caprylic acid precipitation in combination with cationic ion-exchange chromatography. J Immunol Methods 2003; 282: 63-72.
76. R A2P. J Chromatogr B 2005; 814:209-15.
77. Burnouf T, Griffiths E, Padilla A, Seddik S, Stephano MA, Gutiérrez JM. Assessment of the viral safety of antivenoms fractionated from equine plasma. Biologicals 2004; 32: 115-28.
78. Thalley BT, Carroll SB. Rattlesnake and scorpion antivenoms from the egg yolks of immunized hens. Biotechnology 1990; 8: 934-8.
79. Meddeb-Mouelhi F, Bouhaouala-Zahar B, Benlasfar Z, Hammadi M, Mejri T, 'Moslah M, et al. Immunized camel sera and derived immunoglobulin subclasses neutralizing Androctonus austrans hector scorpion toxins. Toxicon 2003; 42: 785-91.
80. Harrison RA, Hasson SS, Harmsen M, Laing GD, Conrath K, Theakston RDG. Neutralisation of venom-induced haemorrhage by IgG, from camels and llamas immunized with viper venom and also by endogenous, non-IgG components in camelid sera. Toxicon 2006; 47: 364-8.
81. Hammers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363: 446-8.
82. Herrera M, León G, Segura A, Meneses F, Lomonte B, Chippaux JP, et al. Factors associated with adverse reactions induced by caprylic acid-fractionated whole IgG preparations: comparison between horse, sheep and camel IgGs. Toxicon 2005; 46: 775-81.
83. Cardoso DF, Yamaguchi IK, Moura da Silva AM. In: Cardoso JLC, Franca FOS, Fan HW, Málaque CMS, Haddad V. Animais Peconhentos no Brasil. Biologia, Clínica e Terapeutica. Sao Paulo, Sarvier 2003; 367-79.
84. Lafaye P, Chournet V, Demangel C, Bon C, Mazie JC. Biologically active human anticrotoxin scFv isolated from a semisynthetic phage library. Immunotechnology 1997; 3: 117-25.
85. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biothechnol 1996; 14: 309-14.
86. Lauwereys M, Ghahroudi MA, Desmyter A, Kinne J, Holzer W, De Genst E, et al. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J 1998; 17: 3512-20.
87. Omidfar K, Rasaee MJ, Modjtahedi H, Forouzandeh M, Taghikhani M, Goldmakani N. Production of a novel camel single-domain antibody specific for the type III mutant EGFR. Tumor Biol 2004; 25: 296-305.
88. Presta L. Antibody engineering for therapeutics. Curr Opin Struct Biol 2003; 13: 519-25.
89. Meyer WP, Habib AG, Onayade AA, Yakubu A, Smith DC, Nasidi A, et al. First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur Serum (Ipser) Africa antivenom. Am J Trop Med Hyg 1997; 56: 291-300.
90. Dart RC, Seifert SA, Boyer LV, Clark RF, Hall E, McKinney P, et al. A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med 2001; 161: 2030-6.
91. Theakston RDG, Reid HA. Development of simple standard assay procedures for the characterization of snake venoms. Bull WHO 1983; 61: 949-56.
92. Gutiérrez JM, Rojas G, Lomonte B, Gené JA, Chaves F, Alvarado J, et al. Standardization of assays for testing the neutralizing ability of antivenoms. Toxicon 1990; 28: 1127-9.
93. Attaran A, Sachs J. Defining and refining international donor support for combating the AIDS pandemic. Lancet 2001; 357: 57-61.
94. Sachs J. A new global commitment to disease control in Africa. Nat Med 2001; 7: 521-3.
95. Gutiérrez JM, Lomonte B. In: Cardoso JLC, Franca FOS, Fan HW, Málaque CMS, Haddad V. Animais Peconhentos no Brasil. Biologia, Clínica e Terapeutica. Sao Paulo, Sarvier 2003; 310-23.
96. Gutiérrez J, Rucavado A. Snake venom metalloproteinases: their role in the pathogenesis of local tissue damage. Biochimie 2000; 82: 841-59.
97. Bode W, Gomis-Ruth FX, Stockler W. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH land Met-turn) and topologies an should be grouped into a common family, the 'metzincins'. FEBS Lett 1993; 331: 134-40.
98. Fox JW, Serrano SMT. Structural considerations of the snake venom metalloproteinases, key members of the M12 reprolysin family of metalloproteinases. Toxicon 2005; 45: 969-85.
99. Gomis-Ruth FX, Kress LF, Kellerman J, Mayr I, Lee X, Huber R, et al. Refined 2 Å X-ray crystal structure of the snake venom zinc-endopeptidase adamalysin II. Primary and tertiary structure determination, refinement, molecular structure and comparison with astacin, collagenase and thermolysin. J Mol Biol 1994; 239: 513-44.
100. Watanabe L, Shannon JD, Valente RH, Rucavado A, Alape-Girón A, Kamiguti AS, et al. Amino acid sequence and crystal structure of BaPI, a metalloproteinase from Bothrops asper snake venom that exerts multiple tissue-damaging activities. Protein Sci 2003; 12: 2273-81.
101. Bjarnason JB, Fox JW. Hemorrhagic metalloproteinases from snake venoms. Pharmacol Ther 1994; 62: 325-72.
102. Kallury R. Basement membranes: structure, assembly and role in tumor angiogenesis. Nat Rev Cancer 2003; 3: 422-33.
103. Hudson BG, Reeders ST, Tryggvason K. Type IV collagen: structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. J Biol Chem 1993; 268: 26033-6.
104. Ownby CL, Bjarnason JB, Tu AT. Hemorrhagic toxins from rattle-snake ( Crotalus atrox) venom. Pathogenesis of hemorrhage induced by three purified toxins. Am J Pathol 1978; 93: 201-18.
105. Moreira L, Borkow G, Ovadia M, Gutiérrez JM. Pathological changes induced by BaH1, a hemorrhagic proteinase isolated from Bothrops asper (terciopelo) snake venom, on mouse capillary blood vessels. Toxicon 1994; 32: 977-87.
106. Gutiérrez JM, Rucavado A, Escalante T, Díaz C. Hemorrhage induced by snake venom metalloproteinases: biochemical and biophysical mechanisms involved in microvessel damage. Toxicon 2005; 45: 997-1011.
107. Gutiérrez JM, Núñez J, Escalante T, Rucavado A. Blood flow is required for rapid endothelial cell damage induced by a snake venom hemorrhagic metalloproteinase. Microvasc Res 2006; 71: 55-63.
108. Lomonte B, Gutiérrez JM, Borkow G, Ovadia M, Tarkowski A, Hanson LÅ. Activity of hemorrhagic metalloproteinase BaH-1 and myotoxin II from Bothrops asper snake venom on capillary endothelial cells in vitro. Toxicon 1994; 32: 505-10.
109. Díaz C, Valverde L, Brenes O, Rucavado A, Gutiérrez JM. Characterization of events associated with apoptosis/anoikis induced by snake venom metalloproteinase BaP1 on human endothelial cells. J Cell Biochem 2005; 94: 520-8.
110. Tanjoni I, Weinlich R, Della-Casa MS, Clissa PB, Saldanha-Gama RF, de Freitas MS, et al. Jararhagin, a snake venom metalloproteinase, induces a specialized form of apoptosis (anoikis) selective to endothelial cells. Apoptosis 2005; 10: 851-61.
111. Baramova EN, Shannon JD, Bjarnason JB, Gonias SL, Fox JW. Interaction of hemorrhagic metalloproteinases with human α-2 macroglobulin. Biochemistry 1990; 29: 1069-74.
112. 1-integrin by the snake venom metalloproteinase jararhagin. Biochem J 1996; 320: 635-41.
113. Harris JB, Cullen MJ. Muscle necrosis caused by snake venoms and toxins. Electron Microsc Rev 1990; 3: 183-211.
114. 2: insights into the mechanisms of local and systemic myotoxicity. Toxicon 2003; 42: 915-31.
115. Dixon RW, Harris JB. Myotoxic activity of the toxic phospholipase, notexin, from the venom of the Australian tiger snake. J Neuropathol Exp Neurol 1996; 55: 1230-7.
116. Melo PA, Burns CF, Blankemeyer JT, Ownby CL. Membrane depolarization is the initial action of crotoxin on isolated murine skeletal muscle. Toxicon 2004; 43: 111-9.
117. 2 isolated from the venom of the snake Bothrops jararacussu. Exp Mol Pathol 1991; 55: 217-29.
118. 2. Trends Pharmacol Sci 1999; 20: 162-70.
119. 2: role of negatively charged phospholipids as potential membrane binding sites. Arch Biochem Biophys 2001; 391: 56-64.
120. Alape-Girón A, Persson B, Cederlund E, Flores-Díaz M, Gutiérrez JM, Thelestam M, et al. Elapid venom toxins: multiple recruitments of ancient scaffolds. Eur J Biochem 1999; 259: 225-34.
121. 2 myotoxins from crotalid snake venoms and their structural determinants of myotoxic action. Toxicon 2003; 42: 885-901.
122. 2 by sequence analysis and site directed mutagenesis. Toxicon 2003; 42: 869-83.
123. Gutiérrez JM, Romero M, Núñez J, Chaves F, Borkow G, Ovadia M. Skeletal muscle necrosis and regeneration after injection of BaH1, a hemorrhagic metalloproteinase isolated from the venom of the snake Bothrops asper (terciopelo). Exp Mol Pathol 1995; 62: 28-41.
124. Franca FOS, Málaque CMS. In: Cardoso JLC, Franca FOS, Fan HW, Málaque CMS, Haddad V. Animais Peconhentos no Brasil. Biologia, Clínica e Terapeutica. Sao Paulo, Sarvier 2003; 72-86.
125. Rucavado A, Núñez J, Gutiérrez JM. Blister formation and skin damage induced by BaP1, a hemorrhagic metalloproteinase from the venom of the snake Bothrops asper. Int J Exp Pathol 1998; 79: 245-54.
126. Rucavado A, Lomonte B, Ovadia M, Gutiérrez JM. Local tissue damage induced by BaP1, a metalloproteinase isolated from Bothrops asper (terciopelo) snake venom. Exp Mol Pathol 1995; 63: 186-99.
127. Anai K, Sugiki M, Yoshida E, Maruyama M. Neutralization of a snake venom hemorrhagic metalloproteinase prevents coagulopathy after subcutaneous injection of Bothrops jararaca venom in rats. Toxicon 2002; 40: 63-8.
128. Tu AT, Hendon RR. Characterization of lizard venom hyaluronidase and evidence for its action as a spreading factor. Comp Biochem Physiol B 1983; 76: 377-83.
129. Giris KS, Shashidharamurthy R, Nagaraju S, Gowda TV, Kemparaju K. Isolation and characterization of hyaluronidase, a "spreading factor" from Indian cobra (Naja naja) venom. Biochimie 2004; 86: 193-202.
130. Saravia-Otten P, Frisan T, Thelestam M, Gutiérrez JM. Membrane independent activation of fibroblast proMMP-2 by snake venom: novel roles for venom proteinases. Toxicon 2004; 44: 749-64.
131. Farsky SHP, Antunes E, Mello SBV. Pro and anti-inflammatory properties of toxins from animal venoms. Curr Drug Targets Inflamm Allergy 2005; 4: 401-11.
132. Lomonte B, Tarkowski A, Hanson LÅ. Host response to Bothrops asper snake venom: analysis of edema formation, inflammatory cells, and cytokine release in a mouse model. Inflammation 1993; 17: 93-105.
133. Rucavado A, Escalante T, Teixeira CFP, Fernandes CM, Díaz C, Gutiérrez JM. Increments in cytokines and matrix metalloproteinases in skeletal muscle after injection of tissue-damaging toxins from the venom of the snake Bothrops asper. Mediat Inflamm 2002; 11: 121-8.
134. 2. Toxicon 2003; 42: 947-62.
135. Zamunér SR, Gutiérrez JM, Muscará MN, Teixeira SA, Teixeira CFP. Bothrops asper and Bothrops jararaca snake venoms trigger microbicidal functions of peritoneal leukocytes in vivo. Toxicon 2001; 39: 1505-13.
136. Zamunér SR, Zuliani JP, Fernandes CM, Gutiérrez JM, Teixeira CFP. Inflammation induced by Bothrops asper venom: release of proinflammatory cytokines and eicosanoids, and role of adhesion molecules in leukocyte infiltration. Toxicon 2005; 46: 806-13.
137. 2 isolated fom Bothrops asper snake venom: role of catalytic activity. Toxicon 2005; 45: 335-46.
138. Chaves F, Teixeira CFP, Gutiérrez JM. Role of nitric oxide in the local and systemic pathophysiological effects induced by Bothrops asper snake venom in mice. Inflanim Res 2006; 55: 245-53.
139. Chacur M, Picolo G, Gutiérrez JM, Teixeira CFP, Cury Y. Pharmacological modulation of hyperalgesia induced by Bothrops asper (terciopelo) snake venom. Toxicon 2001; 39: 1173-81.
140. 2 from Bothrops asper snake venom: pharmacological mediation and molecular determinants. Toxicon 2003; 41: 667-78.
141. Farsky SHP, Walber J, Costa-Cruz M, Cury Y, Teixeira CFP. Leukocyte response induced by Bothrops jararaca crude venom: in vivo and in vitro studies. Toxicon 1997; 35: 185-93.
142. Gallagher P, Bao Y, Serrano SMT, Laing GD, Theakston RDG, Gutiérrez JM, et al. Role of the snake venom toxin jararhagin in proinflammatory pathogenesis: in vitro and in vivo gene expression analysis of the effects of the toxin. Arch Biochem Biophys 2005; 441: 1-15.
143. Clissa PB, Laing GD, Theakston RDG, Mota I, Taylor MJ, Mourada-Silva AM. The effect of jararhagin, a metalloproteinase from Bothrops jararaca venom, on proinflammatory cytokines released by murine peritoneal adherent cells. Toxicon 2001; 39: 1567-73.
144. 2. Toxicon 2005; 46: 523-32.
145. Wei JF, Mo Y2, Quiao LY, Wei XL, Chen HQ, Xie H, et al. Potent histamine-releasing activity of atrahagin, a novel snake venom metalloproteinase. Int J Biochem Cell Biol 2006; 38: 510-20.
146. 2 homologue from Bothrops asper snake venom induces proliferation, apoptosis and necrosis in a lymphoblastoid cell line. Toxicon 2005; 45: 651-60.
147. Tidball JG. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 2005; 288: R345-53.
148. Korthuis RJ, Grisham MB, Granger DN. Leukocyte depletion attenuates vascular injury in postischemic skeletal muscle. Am J Physiol 1988; 254: H823-7.
149. Moilanen E, Whittle B, Moncada S. In: Gallin JI, Snyderman R Eds. Inflammation. Basic Principles and Correlates. Philadelphia, Lippincot 1999; 787-800.
150. Yong VW, Power C, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001; 2: 502-11.
151. Teixeira CFP, Zamuner SR, Zuliani JP, Fernandes CM, Cruz-Hofling MA, Fernandes I, et al. Neutrophils do not contribute to local tissue damage, but play a key role in skeletal muscle regenerarion, in mice injected with Bothrops asper snake venom. Muscle Nerve 2003; 28: 449-59.
152. Chaves F, Teixeira CFP, Gutiérrez JM. Role of TNF-α, IL-1β and IL-6 in the local tissue damage induced by Bothrops asper snake venom: an experimental assessment in mice. Toxicon 2005; 45: 171-8.
153. Teixeira CFP, Chaves F, Zamunér SR, Fernandes CM, Zuliani JP, Cruz-Hofling MA, et al. Effects of neutrophil depletion in the local pathological alterations and muscle regeneration in mice injected with Bothrops jararaca snake venom. Int J Exp Pathol 2005; 86: 107-15.
154. Rodrigues FG, Petretski JH, Kanashiro MM, Lemos L, Dias da Silva W, Kipnis TL. The complement system is involved in acute inflammation but not in the hemorrhage produced by a Bothrops atrox snake venom low molecular mass proteinase. Mol Immunol 2004; 40: 1149-56.
155. Moura-da-Silva AM, Laing GD, Paine MJI, Dennison JMTJ, Politi V, Crampton JM, et al. Processing of pro-tumor necrosis factor-α by venom metalloproteinases: a hypothesis explaining local tissue damage following snake bite. Eur J Immunol 1996; 26: 2000-5.
156. Laing GD, Clissa PB, Theakston RDG, Moura-da-Silva AM, Taylor MJ. Inflammatory pathogenesis of snake venom metalloproteinase-induced skin necrosis. Eur J Immunol 2003; 33: 3458-63.
157. Miyabara EH, Tostes RC, Selistre-de-Araújo HS, Aoki MS, Moriscot AS. Role of nitric oxide in myotoxic activity induced by crotoxin in vivo. Toxicon 2004; 43: 425-32.
158. Grounds M. Towards understanding skeletal muscle regeneration. Path Res Pract 1991; 187: 1-22.
159. Hawke J, Garry DJ. Myogenic satellite cells: physiology to molecular biology. J Appl Physiol 2001; 91: 534-51.
160. León G, Valverde JM, Rojas G, Lomonte B, Gutiérrez JM.
161. 2 antivenoms in the neutralization of hemorrhagic activity of Vipera berus snake venom in mice. Toxicon 1996; 34: 1197-202.
162. Chaves F, Loría GD, Salazar A, Gutiérrez JM. Intramuscular administration of antivenoms in- experimental envenomation by Bothrops asper: comparison between Fab and IgG. Toxicon 2003; 41: 237-44.
163. Yingprasertchai S, Bunyasrisawat S, Ratanabanangkoon K. Hyaluronidase inhibitors (sodium chromoglycate and sodium aurothiomalate) reduce the local tissue damage and prolong the survival time of mice injected with Naja kaouthia and Calloselasma rhodostoma venoms. Toxicon 2003; 42: 635-46.
164. Escalante T, Franceschi A, Rucavado A, Gutiérrez JM. Effectiveness of batimastat, a synthetic inhibitor of matrix metalloproteinases, in neutralizing local tissue damage induced by BaP1, a hemorrhagic metalloproteinase from the venom of the snake Bothrops asper. Biochem Pharmacol 2000; 60: 269-74.
165. 2EDTA. Am J Trop Med Hyg 2000; 63: 313-9.
166. Murakami MT, Arruda EZ, Melo PA, Martinez AB, Calil-Eliás S, Tomaz MA, et al. Inhibition of myotoxic activity of Bothrops asper myotoxin II by the anti-trypanosomal drug suramin. J Mol Biol 2005; 350: 416-26.
167. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999; 274: 21451-4.
168. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
169. Rao BG. Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des 2005; 11: 295-322.
170. Acharya MR, Venitz J, Figg WD, Sparreboom A. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist Updat 2004; 7: 195-208.
171. Hanessian S, Moitessier N, Therrien E. A comparative docking study and the design of potentially selective MMP inhibitors. J Comput Aided Mol Des 2001; 15: 873-81.
172. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-92.
173. D'Alessio S, Gallina C, Gavuzzo E, Giordano C, Gorini B, Mazza F, et al. Inhibition of adamalysin II and MMPs by phosphonate analogues of snake venom peptides. Bioorg Med Chem 1999; 7: 389-94.
174. Brown PD. Ongoing trials with matrix metalloproteinase inhibitors. Exp Opin Invest Drugs 2000; 9: 2167-77.
175. Zhang D, Botos I, Gomis-Ruth FX, Doll R, Blood C, Njoroge FG, et al. Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form D). Proc Natl Acad Sci USA 1994; 91: 8447-51.
176. Botos I, Scapozza L, Zhang D, Liotta LA, Meyer EF. Batimastat, a potent matrix metalloproteinase inhibitor, exhibits an unexpected mode of binding. Proc Natl Acad Sci USA 1996; 93: 2749-54.
177. Francis B, Kaiser II. Inhibition of metalloproteinases in Bothrops asper venom by endogenous peptides. Toxicon 1993; 31: 889-99.
178. Huang KF, Chiou SH, Ko TP, Wang AHJ. Determinants of the inhibition of a Taiwan habu venom metalloproteinase by its endogenous inhibitors revealed by X-ray crystallography and synthetic inhibitor analogues. Eur J Biochem 2002; 269: 3047-56.
179. Munekiyo SM, Mackessy SP. Presence of peptide inhibitors in rattlesnake venoms and their effects on endogenous metalloproteases. Toxicon 2005; 45: 255-63.
180. Soares AM, Ticli FK, Marcussi S, Lourenco MV, Januário AH, Sampaio SV, et al. Medicinal plants with inhibitory properties against snake venoms. Curr Med Chem 2005; 12: 2625-41.
181. Perales J, Neves-Ferreira AGC, Valente RH, Domont GB. Natural inhibitors of snake venom hemorrhagic metalloproteinases. Toxicon 2005; 45: 1013-120.
182. Valente RH, Dragulev B, Perales J, Fox JW, Domont GB. Cloning and characterization of BJ46a, a snake venom metalloproteinase inhibitor from Bothrops jararaca serum. Eur J Biochem 2001; 268: 3042-52.
183. Rucavado A, Escalante T, Gutiérrez JM. Effect of the metalloproteinase inhibitor batimastat in the systemic toxicity induced by Bothrops asper snake venom: understanding the role of metalloproteinases in envenomation. Toxicon 2004; 43: 417-24.
184. Kamiguti AS, Hay CRM, Theakston RDG, Zuzel M. Insights into the mechanism of haemorrhage caused by snake venom metalloproteinases. Toxicon 1996; 34: 627-42.
185. Kamiguti AS. Platelets as targets of snake venom metalloproteinases. Toxicon 2005; 45: 1041-9.
186. 2 enzymes. Prostaglandins Other Lipid Mediat 2002; 68-69: 3-58.
187. 2 and their receptors and binding proteins. Biochim Biophys Acta 2000; 1488: 59-70.
188. 2. J Biol Chem 1994; 269: 13057-60.
189. 2 -a structural review. Toxicon 1996; 34: 827-41.
190. 2 inhibitors in inflammation. Expert Opin Ther Pat 2001; 11: 1123-36.
191. 2 (IIa) with anti-inflammatory activity. Chembiochem 2003; 4: 181-5.
192. 2 protects rats from TNBS-induced colitis. Int Immunopharmacol 2005; 5: 883-92.
193. 2. Toxicon 1989; 27: 613-35.
194. 2 Enzymes: Structure, Function and Mechanisms. Chichester, Wiley 1997; 1-28.
195. 2 enzymes. Toxicon 2003; 42: 827-40.
196. 2 Enzymes: Structure, Function and Mechanisms. Chichester, Wiley 1997; 155-83.
197. Deepa M, Gowda TV. Purification and characterization of a glycoprotein inhibitor of toxic phospholipase from Withania somnifera. Arch Biochem Biophys 2002; 408: 42-50.
198. 2). Toxicon 2005; 46: 751-8.
199. 2 myotoxins. Toxicon 1999; 37: 199-215.
200. Da Silva AJM, Coelho AL, Sima ABC, Moraes RAM, Pinheiro DA, Fernandes FFA, et al. Synthesis and pharmacological evaluation of prenylated and benzylated pterocarpans against snake venoms. Bioorg Med Chem Lett 2004; 14: 431-5.
201. 2 enzymes from habu (Trimeresurus flavoviridis) venom and their interaction with the alkaloid aristolochic acid. Toxicon 1987; 25: 501-15.
202. 2 inhibitor from Cordia verbenacea (Boraginaceae): antiserum action potentiation and molecular interaction. Toxicon 2005; 46: 318-27.
203. 2 and antivenin activity of melanin extracted from Thea sinensis Linn. Life Sci 2004; 74: 2037-47.
204. 2 from Bothrops snake venoms: isolation of 4-narolidylcatechol as active principle. Phytochemistry 2005; 66: 1017-25.
205. 2 by manoalide and manoalogue. Stoichiometry of incorporation. J Biol Chem 1991; 266: 16512-7.
206. 2. Biochem Pharmacol 2003; 66: 1993-2000.
207. 2 from Bothrops asper snake venom. Identification of a heparin-binding and cytolytic toxin region by the use of synthetic peptides and molecular modeling. J Biol Chem 1994; 269: 29867-73.
208. Melo PA, Homsi-Brandeburgo MI, Giglio JR, Suárez-Kurtz G. Antagonism of the myotoxic effects of Bothrops jararacussu venom and bothropstoxin by polyanions. Toxicon 1993; 31: 285-91.
209. 2. Biochimie 2000; 82: 833-40.
210. 2 myotoxin inhibitor proteins from snakes, mammals and plants. Toxicon 2003; 42: 963-77.
211. 2 inhibitors from the blood plasma of the Chinese mamushi, Agkistrodon blomhoffi siniticus. Biochem J 1997; 325: 527-31.
212. 2 binding and antiinflammatory activity. Eur J Biochem 2002; 269: 719-27.
213. Rocha SLG, Lomonte B, Neves-Ferreira AGC, Trugilho MRO, Junqueira-de-Azevedo LM, Ho PL, et al. Functional analysis of DM64, an antimyotoxic protein with immunoglobulin-like structure from Didelphis marsupialis serum. Eur J Biochem 2002; 269: 6052-62.
214. de Oliveira M, Cavalcante WLG, Arruda EZ, Melo PA, Silva MD, Gallacci M. Antagonism of myotoxic and paralyzing activities of bothropstoxin-1 by suramin. Toxicon 2003; 42: 373-9.
215. Stein CA. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 1993; 53: 2239-48.
216. Chan YS, Li Y, Foster W, Fu FH, Huard J. The use of suramin, an antifibrotic agent, to improve muscle recovery after strain injury. Am J Sports Med 2005; 33: 43-51.
217. 2 inhibition for the synthesis of prostaglandins by the plant alkaloid aristolochic acid from a 1.7 Å crystal structure. Biochemistry 2002; 41: 10914-9.
218. 2 from Naja naja sagittifera (group I) and a designed peptide inhibitor Val-Ala-Phe-Arg-Ser (VAFRS) at 1.9 Å resolution reveals unique features. Biochemistry 2003; 42: 11701-6.
219. 2-elaidoylamide complex: a new mode of inhibition. Biochem Biophys Res Commun 2004; 319: 1314-21.
220. Girish KS, Kemparaju K. Inhibition of Naja naja venom hyaluronidase: role in the management of poisonous bite. Life Sci 2006; 78: 1433-40.
221. 2 Enzymes: Structure, Function and Mechanisms. Chichester, Wiley 1997; 205-21.
222. Vital Brazil O. Coral snake venoms: mode of action and pathophysiology of experimental envenomation. Rev Inst Med Trop Sao Paulo 1987; 29: 119-26.
223. Barros SF, Friedlanskaia I, Petricevich VL, Kipnis TL. Local inflammation, lethality and cytokine release in mice injected with Bothrops atrox venom. Mediat Inflamm 1998; 7: 339-46.
224. Avila-Aguero ML, París MM, Peterson PK, Gutiérrez JM, Lomonte B, Faingezicht I. Systemic cytokine response in children bitten by snakes in Costa Rica. Pediatr Emerg Care 2001; 17: 425-9.
225. Petricevich VL, Teixeira CFP, Tambourgi DV, Gutiérrez JM. Increments in serum cytokine and nitric oxide levels in mice injected with Bothrops asper and Bothrops jararaca snake venoms. Toxicon 2000; 38: 1253-66.
226. Szold O, Ben-Abraham R, Weinbroum AA, Englender TE, Ovadia D, Sorkine M, et al. Antagonization of TNF attenuates systemic hemodynamic manifestations of envenomation in a rat model of Vipera aspis snakebite. Intensive Care Med 2001; 27: 884-8.
227. Szold O, Ben-Abraham R, Frolkis I, Sorkine M, Sorkine P. Tumor necrosis factor as a mediator of cardiac toxicity following snake envenomation. Crit Care Med 2003; 31: 1449-53.
228. 2 at 2.0 Å resolution. FEBS Lett 1992; 301: 159-64.
229. 2 from the venom of the cottonmouth snake at 2.0-Å resolution. J Biol Chem 1990; 265: 17649-56.
230. 2 from Agkistrodon piscivorus piscivorus snake venom: synthetic C-terminal peptides from Lys49, but not from Asp49 myotoxins, exert membrane-damaging activities. Toxicon 2001; 39: 1587-94.